40 results about "MTBI - Mild traumatic brain injury" patented technology

Disclosed herein are methods to treat cognition disorders, particularly those associated with aging. The method comprises administering a combination of a carnitine and an oxidant. Preferably the oxidant is thioctic acid. Preferably 0.12 grams to 3 grams of carnitine (particularly ALC) and 0.12 and 1.5 grams of R-alpha-lipoic acid are administered. Optionally, coenzyme Q and/or creatine also are administered. Preferably 10 mg to 500 mg/day of coenzyme Q10 and 1 to 30 grams/day of creatine are administered. The same method can be used to treat cognition deficits associated with carbon monoxide poisoning, mild traumatic brain injury, Type 2 diabetes mellitus, obsessive-compulsive disorder, environmental toxin exposure, and other conditions.

Cognitive assessment systems and methods that provide an integrated solution for evaluating the presence or absence of cognitive impairment. The present invention is used to test cognitive functions of an individual including information processing speed, working memory, work list learning and recall, along with variations of these tasks. Immersive and non-immersive systems and methods are disclosed. Testing and results feedback using the present invention may be completed in real time, typically in less than 15 minutes.

Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described.

The present disclosure provides systems and methods for evaluating a brain scan using reference data. Specifically, the systems and methods include a computed tomography (CT) scanner for the purpose of diagnosing concussions or mild traumatic brain injuries (mTBI). The system includes a multi-energy x-ray source (i.e., spectral CT), a photon counting x-ray detector, and a content-aware computer aided diagnostic (CAD) algorithm designed to detect imperceptible changes indicative of structural and physiological damage caused by a concussive event by comparing raw volumetric datasets of baseline (healthy) reference scan data to patient scan data taken after a concussive event.

Compositions and methods for treating traumatic brain injury (TBI) and mild traumatic brain injury (mTBI) using progesterone and ent-progesterone are described.

The disclosure provides for easy, reliable, and rapid screening of a mild traumatic brain injury (mTBI) based on a modeling of a subject's tracking of a dynamic target during the course of a simple motor tracking task. The gathered tracking data can be used to calculate tracking errors between the subject's actual input (e.g., grip force) and the intended target input. The tracking errors may be used to generate numerical values for model parameters that correlate the subject's responses to the tracking errors during the course of the dynamic motor tracking task. A classification model may be used to compare the model values to multi-subject model values of known diagnoses for mTBI. The entire screening process can be effectively administered in a matter of minutes or less, and with a high degree of accuracy.

A method and composition for reducing the recovery time for a human suffering from mild traumatic brain injury are provided. The composition is a mixture of component supplements that synergistically address the symptoms of the condition and the damage done by the injury.

The present disclosure provides methods of maintaining brain function, memory function and reducing the prevalence of mild traumatic brain injury in an individual at risk of experiencing a mild traumatic brain injury. The present disclosure also provides methods for administering various human dietary supplements to individuals at risk of experiencing a mild traumatic brain injury.

The present invention relates to a method of determining whether a subject has suffered a mild traumatic brain injury. The method comprises selecting a subject exposed to a head trauma and determining an apoA-1 level in a body fluid sample obtained from the selected subject, wherein a decreased apoA-1 level in the body fluid sample indicates that the subject has suffered a mild traumatic brain injury. The invention also relates to a kit for determining whether a subject has suffered a mild traumatic brain injury.

Provided herein is a method of transfecting a brain cell of a subject with a polynucleotide comprising systemically administering to the subject a composition comprising a micelle having a hydrophobic superparamagnetic iron oxide nanoparticle (SPION) core, a first coating comprising a cationic polymer, and a second coating comprising the polynucleotide, wherein the subject has a mild traumatic brain injury.